Relation between donor-recipient HLA mismatching and combined malignant tumor after renal transplantation
-
摘要:
目的 研究肾移植供受体人类白细胞抗原(HLA)错配与术后并发恶性肿瘤的关系。 方法 对1993年至2009年在首都医科大学附属北京友谊医院泌尿科行肾移植手术5年以上,且有完整的供受体HLA分型的1 021例患者的临床资料进行研究。1 021例肾移植术后患者中,非肿瘤患者928例,恶性肿瘤患者93例。收集供受者HLA-A、B和DR 3个位点共6个抗原的错配情况,分析供受体HLA错配数与肾移植术后发生恶性肿瘤的关系,以及不同性别肾移植患者的供受体HLA错配数与术后发生恶性肿瘤的关系。 结果 1 021例患者中9.11%(93/1 021)发生恶性肿瘤。HLA错配0~1,2、3、4、5和6个抗原的患者恶性肿瘤发生率分别为14%、13%、14%、6%、3%和4%。HLA半相合以上(HLA错配0~3个)患者的恶性肿瘤发生率明显高于HLA半相合以下(HLA错配4~6个)患者(14%比5%,χ2=24.11,P<0.005)。恶性肿瘤患者中,HLA半相合以上的男性和女性患者分别为12例和54例;HLA半相合以下的男性和女性患者分别为12例和15例, HLA半相合以上患者中女性患者所占比例高于男性患者(χ2=5.60,P<0.025)。 结论 HLA配错数越低的肾移植患者特别是女性患者,其恶性肿瘤发生率越高。 Abstract:Objective To study the relation between donor-recipient human leukocyte antigen (HLA) mismatching and combined malignant tumors after renal transplantation. Methods Clinical data of 1 021 patients who received renal transplantation from 1993 to 2009 in Department of Urology of Beijing Friendship Hospital of Affiliated Capital University of Medical Sciences over 5 years and had complete HLA typing were analyzed. In the 1 021 patients after renal transplantation, 928 cases were non-tumor patients and 93 cases were malignant tumor patients. The mismatching data of 3 locus (HLA-A, B and DR) with a total of 6 antigens of the donors and recipients were collected. The relation between donor-recipient HLA mismatching number and postoperative combined malignant tumors was analyzed. And that between genders was also analyzed. Results Malignant tumors occurred in 9.11%(93/1 021)of the patients. The malignant tumor incidences of patients with HLA mismatch of 0-1, 2, 3, 4, 5 and 6 antigens were 14%, 13%, 14%, 6%, 3% and 4% respectively. Patients with HLA over half-matched (0-3 antigens mismatch) had higher incidence of malignant tumors compared with that in patients with HLA less than half matched (4-6 antigens mismatch) (14% vs. 5%;χ2=24.11,P<0.005). In the malignant tumor patients of 0-3 antigens mismatch, 12 cases were males and 54 cases were females. In the patients of 4-6 antigens mismatch, 12 cases were males and 15 cases were females. The proportion of female patients of 0-3 antigens mismatch was higher than that of male patients(χ2=5.60,P<0.025). Conclusions For the renal transplant patients, especially female patients, the lower the HLA mismatching number is, the higher the malignant tumor incidence is. -
Key words:
- Renal transplantation /
- Human leukocyte antigen /
- Matching /
- Malignant tumor /
- Female
-
表 1 HLA错配数与肾移植术后发生恶性肿瘤的关系
Table 1. The relation between HLA mismatching number and occurrence of malignant tumor after renal transplantation (n)
HLA错配 数(个) n 非肿瘤 患者 肿瘤 患者 肿瘤发生率 (%) 0～1 14 12 2 14 2 131 114 17 13 3 327 280 47 14 4 304 286 18 6 5 176 170 6 3 6 69 66 3 4 合计 1 021 928 93 9.11 
下载: 导出CSV
表 2 不同性别肾移植患者的HLA错配数与术后发生恶性肿瘤的关系
Table 2. The relation between HLA mismatching number and occurrence of malignant tumor after renal transplantation in different genders(n)
HLA错配 数(个) n 非肿瘤患者 肿瘤患者 男性 女性 男性 女性 0～1 14 8 4 0 2 2 131 66 48 6 11 3 327 178 102 6 41 4 304 182 104 7 11 5 176 102 68 2 4 6 69 39 27 3 0 合计 1 021 575 353 24 69
下载: 导出CSV
-
[1] 牛斌,林静,陈晓瑜,等.肾移植术后新发恶性肿瘤临床分析[J].器官移植, 2013, 4(2):91-94. http://www.organtranspl.com/browse/detail/qkid/63/id/309.htmlNiu B, Lin J, Chen XY, et al. Clinical analysis of de novo malignancies after renal transplantation[J]. Organ Transplant,2013,4(2):91-94. http://www.organtranspl.com/browse/detail/qkid/63/id/309.html [2] 田普训,薛武军,丁小明,等.影响肾移植受者长期存活的多因素分析——单中心989例经验总结[J].中华器官移植杂志,2012,33(12):706-709. http://cdmd.cnki.com.cn/Article/CDMD-90024-2004136501.htmTian PX, Xue WJ, Ding XM, et al. A multifactorial analysis on long-term survival of kidney transplantation recipients: a report of 989 cases in one centre[J]. Chin J Organ Transplant,2012,33(12):706-709. http://cdmd.cnki.com.cn/Article/CDMD-90024-2004136501.htm [3] 杨庆,肖成武,王林辉,等.肾移植术后自体泌尿系统肿瘤25例临床分析[J].中华器官移植杂志,2012,33(7):397-399.Yang Q, Xiao CW, Wang LH, et al. Clinical analysis of 25 cases of autologous urological neoplasms in renal transplant recipients[J]. Chin J Organ Transplant, 2012,33(7):397-399. [4] Apel H, Walschburger-Zorn K, Häberle L, et al. De novo malignancies in renal transplant recipients: experience at a single center with 1882 transplant patients over 39 yr[J]. Clin Transplant,2013,27(1):E30-E36. doi: 10.1111/ctr.2013.27.issue-1 [5] Yunus M, Aziz T, Mubarak M. Posttransplant malignancies in renal transplant recipients: 22-years experience from a single center in Pakistan[J]. Asian Pac J Cancer Prev,2012,13(2):575-578. doi: 10.7314/APJCP.2012.13.2.575 [6] Bottomley MJ, Harden PN. Update on the long-term complications of renal transplantation[J]. Br Med Bull,2013,106:117-134. doi: 10.1093/bmb/ldt012 [7] Rocha A, Malheiro J, Fonseca I, et al. Noncutaneous neoplasms after kidney transplantation: analysis at single center[J]. Transplant Proc,2013,45(3):1102-1105. doi: 10.1016/j.transproceed.2013.02.005 [8] Hibberd AD, Trevillian PR, Wlodarczyk JH, et al. Effect of immunosuppression for primary renal disease on the risk of cancer in subsequent renal transplantation: a population-based retrospective cohort study[J]. Transplantation,2013,95(1):122-127. doi: 10.1097/TP.0b013e3182782f59 [9] Karczewski M, Czapiewski W, Karczewski J. Urologic de novo malignancies after kidney transplantation: a single center experience[J].Transplant Proc, 2012, 44(5):1293-1297. doi: 10.1016/j.transproceed.2011.11.063 [10] Ruangkanchanasetr P, Lauhawatana B, Leawseng S, et al. Malignancy in renal transplant recipients: a single-center experience in Thailand[J]. J Med Assoc Thai,2012,95(Suppl 5):S12-S16. http://cn.bing.com/academic/profile?id=142869489&encoded=0&v=paper_preview&mkt=zh-cn [11] Hutton B, Joseph L, Yazdi F, et al. Checking whether there is an increased risk of post-transplant lymphoproliferative disorder and other cancers with specific modern immunosuppression regimens in renal transplantation: Protocol for a network meta-analysis of randomized and observational studies[J]. Syst Rev, 2014,3(1):16. doi: 10.1186/2046-4053-3-16 [12] Serre JE, Michonneau D, Bachy E, et al. Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival[J]. Kidney Int,2014,85(1):182-190. doi: 10.1038/ki.2013.253 [13] Longmore DK, Conwell LS, Burke JR, et al. Post-transplant lymphoproliferative disorder: no relationship to recombinant human growth hormone use in Australian and New Zealand pediatric kidney transplant recipients[J]. Pediatr Transplant, 2013,17(8):731-736. doi: 10.1111/petr.2013.17.issue-8 [14] Khedmat H, Taheri S. Ultra-early onset post-transplantation lymphoproliferative disease[J]. Saudi J Kidney Dis Transpl,2013,24(6):1144-1152. doi: 10.4103/1319-2442.121270 [15] 唐睿珠,雷雨,李继梅,等.HLA-A*02等位基因与云南宣威肺癌相关性研究[J].中国免疫学杂志,2010,26(7):624-626,638. http://www.cnki.com.cn/Article/CJFDTOTAL-ZMXZ201007012.htmTang RZ, Lei Y, Li JM, et al. The study on HLA-A*02 allele frequency and its relationship with the susceptibility to lung cancer in Yunnan Xuanwei[J]. Chin J Immunol,2010,26(7):624-626,638. http://www.cnki.com.cn/Article/CJFDTOTAL-ZMXZ201007012.htm [16] 马斌,郭鑫,高平,等.HLA-DRB1及DQB1等位基因多态性与宁夏回族人群食管癌的关联性研究[J].宁夏医学杂志,2010,32(11):987-989,前插4. http://www.cnki.com.cn/Article/CJFDTOTAL-NXYX201011007.htmMa B, Guo X, Gao P, et al. Associative study of polymorphisms of HLA-DRB1 and DQB1 in genetic susceptibility to esophageal cancer in Ningxia Hui ethnic[J]. Ningxia Med J,2010,32(11):987-989, front insert 4. http://www.cnki.com.cn/Article/CJFDTOTAL-NXYX201011007.htm [17] 彭明强,杨志豪,方自林,等.国内公开报道的肾移植后并发恶性肿瘤病例的总结分析[J].中华器官移植杂志,2005,26(5):269-271. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHQG200505003.htmPeng MQ, Yang ZH, Fang ZL, et al. An assemble analysis of malignancy following renal transplantation in China[J]. Chin J Organ Transplant,2005,26(5):269-271. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHQG200505003.htm -
下载: 
点击查看大图
表(2)
计量
- 文章访问数: 130
- HTML全文浏览量: 44
- PDF下载量: 8
- 被引次数: 0
